RedFuMOS provides a flexible framework for integrating heterogeneous multi-omics and clinical data and includes a dimensionality reduction step to mitigate the curse of dimensionality, which confirmed that, although computationally expensive, the dimensionality reduction step is crucial for achieving good stratification performance.
Abstract
Background. Patient stratification from multi-omics and clinical data is essential for uncovering disease heterogeneity and moving toward more personalized treatment strategies. However, integrating heterogeneous data layers while identifying robust patient strata remains challenging. Methods. We introduce Reduced Fusion of Multi-Omics Stratification (RedFuMOS), a novel three-step approach for patient stratification based on mixed-type multi-omics data. RedFuMOS extends Similarity Network Fusion to accommodate mixed-type data layers and layer-specific similarity measures for data integration, includes a dimensionality reduction step to mitigate the curse of dimensionality, and performs patient stratification using density-based hierarchical clustering with HDBSCAN. It also implemented an automated optimization procedure to identify the best set of hyperparameters, minimizing the need for manual tuning. Results. RedFuMOS outperformed six state-of-the-art tools for multi-omics patient stratification in a comprehensive simulated benchmarking study, which also confirmed that, although computationally expensive, the dimensionality reduction step is crucial for achieving good stratification performance. Additionally, RedFuMOS identified two clinically relevant patient strata in a small real-world cohort of patients with Philadelphia chromosome-positive chronic myeloid leukaemia. Conclusion. RedFuMOS provides a flexible framework for integrating heterogeneous multi-omics and clinical data. RedFuMOS is available as an R package at http://github.com/delucasara/RedFuMOS.
BackgroundAlzheimer's disease (AD), the most prevalent subtype of dementia, is characterized by a gradual decline in brain cognitive function. Early detection is critical for initiating timely interventions that may delay the severe progression of the disease. Recent advances in next-generation sequencing (NGS) offer p...
Multi-omics integration has become central to precision medicine, yet in real-world clinical cohorts, complete multi-layer profiling is rarely achieved. Cost, assay failure, and evolving study design frequently produce block-wise modality missingness, where entire omics layers are absent for subsets of patients. This...
R. Nguyen, F. Vafaee· Artificial Intelligence Revi...· 0 citations
WGCNA+ detects biologically meaningful modules, cross-omics feature and phenotype correlations, and provides AI-powered interpretation that accelerates research, making it an innovative, powerful tool for clinical and translational research.
Antonino Zito, Xavier Montagut, Santiago Cano-Muniz et al.· bioRxiv· 0 citations
Multi-omics studies provide opportunities to investigate complex biological systems, but their interpretation can be complicated by numerous sources of variation. Here, we discuss the biological, analytical, and computational factors that can affect the reproducibility of omics studies. We introduce practical recommend...
The SeqUIaSCOPE platform combines molecular-level validation via embedded genome browsing with systems-level interpretation through dynamic pathway visualization, enabling geneticists to assess how alterations converge across biological networks.
Kateřina Jurásková, P. Pokorna, Kristián Kováč et al.· Bioinformatics· 0 citations
BACKGROUND
Coronary artery disease (CAD) remains the leading cause of global mortality. Multi-omics integration offers unprecedented opportunities for precision risk stratification beyond conventional approaches. However, comprehensive integration of genomic, proteomic, and metabolomic data for CAD prediction remains u...
Qiang Su, Qiu-Yan Li, Chen-Kai Hu et al.· Ageing Research Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.